Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Cardurion was founded by physician-scientists with world-class expertise in cardiovascular signaling pathways, and a shared passion to find and develop a pipeline of novel treatment options to improve the lives of patients. Cardurion has two groundbreaking clinical programs in development, a first-in-class phosphodiesterase-9 (PDE9) inhibitor for both types of heart failure and the first-ever clinical-stage Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor for rare and common cardiovascular diseases.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/16/24	$260,000,000	Series B	Ascenta Capital Bain Capital Life Sciences Blue Owl Delos Capital Digitalis Ventures Farallon Capital Management Fidelity Management & Research Company GV Invus Capital Millennium Management NEA Ventures	undisclosed